Activist investor Starboard Value takes $1 bln stake in Pfizer, sources say
Updates Oct. 6 story to add premarket share move in paragraph 5, analyst comment in paragraph 7
Oct 6 (Reuters) -Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer PFE.N and wants the U.S. drug giant to make changes to turn its performance around, sources familiar with the matter said on Sunday.
Starboard has also approached Ian Read, a former Pfizer CEO, and Frank D'Amelio, who served as CFO until 2021, and both have expressed interest in helping the activist investor, the sources said.
Read served as CEO until Albert Bourla took the position in 2019. Bourla was instrumental in working with BioNTech to develop a COVID-19 vaccine.
Pfizer declined to comment and Starboard did not immediately respond to a Reuters request for comment.
Shares of the drugmaker rose 2.2% to $29.20 in premarket trading on Monday. They have fallen over 13% in the past year and trade at around half their pandemic-era highs as sales of its COVID products shrink.
Wall Street analysts said there was no quick fix by an activist investor to solve Pfizer's many problems.
"We await future developments, but we do not see low-hanging fruit to boost shareholder value," Leerink Partners analyst David Risinger wrote in a research note.
Pfizer has struggled to find a product that would make up for the lost revenue from its COVID vaccine and pill.
It had aweaker-than-hoped launch of its respiratory syncytial virus (RSV) vaccine and clinical data froman obesity pill it was developing has been disappointing.
CEO Bourla has also spent some $70 billion since 2020 on acquisitions, while launching cost-saving initiatives.
Pfizer bought Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics (GBT) for $5 billion and Trillium for $2 billion.
The Wall Street Journal first reported the newsof Starboard's stake.
The investment firm has previously pushed for changes at News Corp NWSA.O, Salesforce CRM.N and Tinder-owner MatchGroup MTCH.O.
Reporting by Svea Herbst-Bayliss in New York, Surbhi Misra and Kashish Tandon in Bengaluru; Editing by Tom Hogue, Jacqueline Wong and Anil D'Silva
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
